Last month, a three-judge panel of the U.S. Court of Appeals for the Second Circuit vacated a $147 million lower court verdict and freed a Chinese pharmaceutical maker from U.S. antitrust liability for price-fixing on the basis of international comity.
While the decision might have been a disappointment to many in the United States, it was hailed in China as a victorious ending to a 12-year-long litigation marathon. State-run news agency Xinhua said, quoting a local legal official in the northern Hebei province, that the case could set an example for other Chinese exporters facing similar antitrust allegations in the U.S. And DeHeng Law Offices, the Beijing-based law firm that served as Chinese counsel for defendants-appellants Hebei Welcome Pharmaceutical Co. Ltd. and its parent, North China Pharmaceutical Group Corp., said in a statement that “this victory has the significance of a milestone to Chinese companies in their dealings with cross-border litigation.”
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
